One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Curbing the climb in cancer incidence
doi : 10.1016/S1470-2045(24)00217-1
Volume 25, Issue 5, May 2024, Page 529
Cancer and incarceration: a call for action
Ilana B Richman, *Cary P Gross, Emily A Wang
doi : 10.1016/S1470-2045(24)00201-8
Volume 25, Issue 5, May 2024, Pages 530-531
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
*Nadine Houédé, Kevin Hebert
doi : 10.1016/S1470-2045(24)00179-7
Volume 25, Issue 5, May 2024, Pages 531-533
No prime time yet for checkpoint inhibitors in localised head and neck squamous cell carcinoma
Jens Voortman
doi : 10.1016/S1470-2045(24)00197-9
Volume 25, Issue 5, May 2024, Pages 533-534
Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?
Margaret E Wierman
doi : 10.1016/S1470-2045(24)00151-7
Volume 25, Issue 5, May 2024, Pages 534-535
Olanzapine for chemotherapy-induced nausea and vomiting control
Venkatraman Radhakrishnan, Ramakrishnan Ayloor Seshadri, Sreekumaran Nair
doi : 10.1016/S1470-2045(24)00091-3
Volume 25, Issue 5, May 2024, Page e174
Olanzapine for chemotherapy-induced nausea and vomiting control
*Vinod Sharma, Apoorva Dadheech, Atul Yadav, Jitendra Kumar Pehalajani, Naresh Somani
doi : 10.1016/S1470-2045(24)00129-3
Volume 25, Issue 5, May 2024, Page e175
Olanzapine for chemotherapy-induced nausea and vomiting control
Seiji Tsuruta, Kunihito Matsuguma, Naruaki Kawasaki, Ayaka Ishikawa, Hiroto Ishiki
doi : 10.1016/S1470-2045(24)00092-5
Volume 25, Issue 5, May 2024, Page e176
Olanzapine for chemotherapy-induced nausea and vomiting control – Authors’ reply
Jyoti Bajpai, Akash Pawar, Venkatesh Kapu, Kumar Prabhash
doi : 10.1016/S1470-2045(24)00195-5
Volume 25, Issue 5, May 2024, Page e177
Alternative approaches to risk–benefit balancing in immunotherapy
Yusuf Ilhan, *Yakup Ergun
doi : 10.1016/S1470-2045(24)00085-8
Volume 25, Issue 5, May 2024, Page e178
Evaluating cancer care in low-income and middle-income countries
Vrindha Pari, Bharath Kumar Tirupakuzhi Vijayaraghavan, Bruce M Biccard, Madiha Hashmi
doi : 10.1016/S1470-2045(24)00150-5
Volume 25, Issue 5, May 2024, Page e179
Correction to Lancet Oncol 2023; 24: 1094–108
doi : 10.1016/S1470-2045(24)00209-2
Volume 25, Issue 5, May 2024, Page e180
1 in 9 USA cancer diagnoses missed during 2020 COVID-19 pandemic
doi : 10.1016/S1470-2045(24)00154-2
Volume 25, Issue 5, May 2024, Page 536
EPA ruling to ban chrysotile asbestos
Talha Burki
doi : 10.1016/S1470-2045(24)00155-4
Volume 25, Issue 5, May 2024, Page 537
Arsenic contamination and cancer risk in Bangladesh
Manjulika Das
doi : 10.1016/S1470-2045(24)00156-6
Volume 25, Issue 5, May 2024, Page 538
Environmental pollution and cancer risk in La Oraya, Peru
Manjulika Das
doi : 10.1016/S1470-2045(24)00184-0
Volume 25, Issue 5, May 2024, Page 540
UK tobacco and vapes bill one step closer
Priya Venkatesan
doi : 10.1016/S1470-2045(24)00185-2
Volume 25, Issue 5, May 2024, Page 541
Expansion of radiotherapy access in Ethiopia
Manjulika Das
doi : 10.1016/S1470-2045(24)00194-3
Volume 25, Issue 5, May 2024, Page 542
Study bolsters concerns about US FDA accelerated drug approvals
Bryant Furlow
doi : 10.1016/S1470-2045(24)00205-5
Volume 25, Issue 5, May 2024, Page 543
Nigeria revitalises national cancer response with new initiatives
Paul Adepoju
doi : 10.1016/S1470-2045(24)00206-7
Volume 25, Issue 5, May 2024, Page 544
Cancer Workforce Fund launched to address oncology workforce crisis
Emma Wilkinson
doi : 10.1016/S1470-2045(24)00207-9
Volume 25, Issue 5, May 2024, Page 545
Advisory Group recommendations on priorities for the IARC Monographs
Karima El Rhazi, Lin Fritschi, Shoji Fukushima, Lode Godderis, Manolis Kogevinas, Dirk W Lachenmeier, Daniele Mandrioli, Mazvita M Muchengeti, Richard T Niemeier, Jane J Pappas, Jingbo Pi, Mark P Purdue, Elio Riboli, Teresa RodrÃguez, Vivi Schlünssen, Lamia Benbrahim-Tallaa, Aline de Conti, Caterina Facchin, Elisa Pasqual, Roland Wedekind, Ayat Ahmadi, Shirisha Chittiboyina, Zdenko Herceg, Shalini Kulasingam, Béatrice Lauby-Secretan, Richard MacLehose, Moez Sanaa, Joachim Schüz, Eero Suonio, Jiri Zavadil, Heidi Mattock, Federica Madia, Mary K Schubauer-Berigan
doi : 10.1016/S1470-2045(24)00208-0
Volume 25, Issue 5, May 2024, Pages 546-548
US EPA sets historic new restrictions on toxic PFAS in drinking water
Bryant Furlow
doi : 10.1016/S1470-2045(24)00215-8
Volume 25, Issue 5, May 2024, Page e181
Proposed bill to support assisted dying in France
Sharmila Devi
doi : 10.1016/S1470-2045(24)00216-X
Volume 25, Issue 5, May 2024, Page e182
The fate of sotorasib: a regulatory failure potentially harming patients
Sruthi Ranganathan, Vinay Prasad, *Timothée Olivier
doi : 10.1016/S1470-2045(23)00616-2
Volume 25, Issue 5, May 2024, Pages 549-552
Cancer incidence, treatment, and survival in the prison population compared with the general population in England: a population-based, matched cohort study
Margreet Lüchtenborg, Jennie Huynh, Jo Armes, Emma Plugge, Rachael M Hunter, Renske Visser, Rachel M Taylor, Elizabeth A Davies
doi : 10.1016/S1470-2045(24)00035-4
Volume 25, Issue 5, May 2024, Pages 553-562
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M Joshua, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J Francis, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Craig Gedye, Natalie K Rutherford, Shahneen Sandhu, Aravind Ravi Kumar, David Pook, Shakher Ramdave, David P Nadebaum, Mark Voskoboynik, Andrew D Redfern, William Macdonald, Laurence Krieger, Geoff Schembri, Wei Chua, Peter Lin, Lisa Horvath, Patricia Bastick, Patrick Butler, Alison Yan Zhang, Sonia Yip, Hayley Thomas, Ailsa Langford, Michael S Hofman, Margaret McJannett, Andrew James Martin, Martin R Stockler*, Ian D Davis*, for the ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Groupâ€
doi : 10.1016/S1470-2045(24)00135-9
Volume 25, Issue 5, May 2024, Pages 563-571
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
Jean-Pascal Machiels, Yungan Tao, Lisa Licitra, Barbara Burtness, Makoto Tahara, Danny Rischin, Gustavo Alves, Iane Pinto Figueiredo Lima, Brett G M Hughes, Yoann Pointreau, Sercan Aksoy, Simon Laban, Richard Greil, Martin Burian, Marcin HetnaÅ‚, Jean-Pierre Delord, Ricard MesÃa, Miren Taberna, John N Waldron, Christian Simon, Vincent Grégoire, Kevin J Harrington, Ramona F Swaby, Yayan Zhang, Burak Gumuscu, Behzad Bidadi, Lillian L Siu, on behalf of the KEYNOTE-412 Investigators
doi : 10.1016/S1470-2045(24)00100-1
Volume 25, Issue 5, May 2024, Pages 572-587
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
Ana Oaknin, Kathleen Moore, Tim Meyer, José López-Picazo González, Lot A Devriese, Asim Amin, Christopher D Lao, Valentina Boni, William H Sharfman, Jong Chul Park, Makoto Tahara, Suzanne L Topalian, Manuel Magallanes, Alejandro Molina Alavez, Tariq Aziz Khan, Catherine Copigneaux, Michelle Lee, Charlie Garnett-Benson, Xuya Wang, R Wendel Naumann
doi : 10.1016/S1470-2045(24)00088-3
Volume 25, Issue 5, May 2024, Pages 588-602
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study
Anna van der Voort, Fleur M Louis, Mette S van Ramshorst, Rob Kessels, Ingrid A Mandjes, Inge Kemper, Mariette J Agterof, Wim A van der Steeg, Joan B Heijns, Marlies L van Bekkum, Ester J Siemerink, Philomeen M Kuijer, Astrid Scholten, Jelle Wesseling, Marie-Jeanne T F D Vrancken Peeters, Ritse M Mann, Gabe S Sonke, on behalf of the Dutch Breast Cancer Research Group
doi : 10.1016/S1470-2045(24)00104-9
Volume 25, Issue 5, May 2024, Pages 603-613
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial
Tanja Fehm, Francesco Cottone, Kyle Dunton, Fabrice André, Ian Krop, Yeon Hee Park, Michelino De Laurentiis, Yasuo Miyoshi, Anne Armstrong, Manuel Ruiz Borrego, Rinat Yerushalmi, Francois P Duhoux, Toshimi Takano, Wenjing Lu, Anton Egorov, Sung-Bae Kim
doi : 10.1016/S1470-2045(24)00128-1
Volume 25, Issue 5, May 2024, Pages 614-625
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
Howard A Burris III, Takuji Okusaka, Arndt Vogel, Myung Ah Lee, Hidenori Takahashi, Valeriy Breder, Jean-Frédéric Blanc, Junhe Li, Melinda Bachini, Magdalena Żotkiewicz, Jayne Abraham, Nikunj Patel, Julie Wang, Muzammil Ali, Nana Rokutanda, Gordon Cohen, Do-Youn Oh
doi : 10.1016/S1470-2045(24)00082-2
Volume 25, Issue 5, May 2024, Pages 626-635
Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study
Lance Turtle*, Sarah Elliot*, Thomas M Drake*, Mathew Thorpe, Emma G Khoury, William Greenhalf, Hayley E Hardwick, Gary Leeming, Andy Law, Wilna Oosthuyzen, Riinu Pius, Catherine A Shaw, J Kenneth Baillie, Peter J M Openshaw, Annemarie B Docherty, Malcolm G Semple†, Ewen M Harrison†, Carlo Palmieri†, on behalf of the ISARIC4C Investigators
doi : 10.1016/S1470-2045(24)00107-4
Volume 25, Issue 5, May 2024, Pages 636-648
Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial
Matthew T Campbell, Vania Balderrama-Brondani, Camilo Jimenez, Gina Tamsen, Leonardo P Marcal, Jeena Varghese, Amishi Y Shah, James P Long, Miao Zhang, Joshua Ochieng, Cara Haymaker, Mouhammed Amir Habra
doi : 10.1016/S1470-2045(24)00095-0
Volume 25, Issue 5, May 2024, Pages 649-657
Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial
Camilo Jimenez, Mouhammed Amir Habra, Matthew T Campbell, Gina Tamsen, Damaris Cruz-Goldberg, James Long, Roland Bassett, Robert Dantzer, Vania Balderrama-Brondani, Jeena Varghese, Yang Lu
doi : 10.1016/S1470-2045(24)00133-5
Volume 25, Issue 5, May 2024, Pages 658-667
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study
Ayse Bahar Ercan, Melyssa Aronson, Nicholas R Fernandez, Yuan Chang, Adrian Levine, Zhihui Amy Liu, Logine Negm, Melissa Edwards, Vanessa Bianchi, Lucie Stengs, Jiil Chung, Abeer Al-Battashi, Agnes Reschke, Alex Lion, Alia Ahmad, Alvaro Lassaletta, Alyssa T Reddy, Amir F Al-Darraji, Amish C Shah, An Van Damme, Anne Bendel, Aqeela Rashid, Ashley S Margol, Bethany L Kelly, Bojana Pencheva, Brandie Heald, Brianna Lemieux-Anglin, Bruce Crooks, Carl Koschmann, Catherine Gilpin, Christopher C Porter, David Gass, David Samuel, David S Ziegler, Deborah T Blumenthal, Dennis John Kuo, Dima Hamideh, Donald Basel, Dong-Anh Khuong-Quang, Duncan Stearns, Enrico Opocher, Fernando Carceller, Hagit Baris Feldman, Helen Toledano, Ira Winer, Isabelle Scheers, Ivana Fedorakova, Jack M Su, Jaime Vengoechea, Jaroslav Sterba, Jeffrey Knipstein, Jordan R Hansford, Julieta Rita Gonzales-Santos, Kanika Bhatia, Kevin J Bielamowicz, Khurram Minhas, Kim E Nichols, Kristina A Cole, Lynette Penney, Magnus Aasved Hjort, Magnus Sabel, Maria Joao Gil-da-Costa, Matthew J Murray, Matthew Miller, Maude L Blundell, Maura Massimino, Maysa Al-Hussaini, Mazin F Al-Jadiry, Melanie A Comito, Michael Osborn, Michael P Link, Michal Zapotocky, Mithra Ghalibafian, Najma Shaheen, Naureen Mushtaq, Nicolas Waespe, Nobuko Hijiya, Noemi Fuentes-Bolanos, Olfat Ahmad, Omar Chamdine, Paromita Roy, Pavel N Pichurin, Per Nyman, Rachel Pearlman, Rebecca C Auer, Reghu K Sukumaran, Rejin Kebudi, Rina Dvir, Robert Raphael, Ronit Elhasid, Rose B McGee, Rose Chami, Ryan Noss, Ryuma Tanaka, Salmo Raskin, Santanu Sen, Scott Lindhorst, Sebastien Perreault, Shani Caspi, Shazia Riaz, Shlomi Constantini, Sophie Albert, Stanley Chaleff, Stefan Bielack, Stefano Chiaravalli, Stuart Louis Cramer, Sumita Roy, Suzanne Cahn, Suzanne Penna, Syed Ahmer Hamid, Tariq Ghafoor, Uzma Imam, Valerie Larouche, Vanan Magimairajan Issai, William D Foulkes, Yi Yen Lee, Paul C Nathan, Yosef E Maruvka, Mary-Louise C Greer, Carol Durno, Adam Shlien, Birgit Ertl-Wagner, Anita Villani, David Malkin, Cynthia Hawkins, Eric Bouffet, Anirban Das*, Uri Tabori
doi : 10.1016/S1470-2045(24)00026-3
Volume 25, Issue 5, May 2024, Pages 668-682
Considerations for using potential surrogate endpoints in cancer screening trials
Alexis B Webb, Christine D Berg, Philip E Castle, David Crosby, Ruth Etzioni, Larry G Kessler, Usha Menon, Mahesh Parmar, Robert J C Steele, Peter D Sasieni
doi : 10.1016/S1470-2045(24)00015-9
Volume 25, Issue 5, May 2024, Pages e183-e192
Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology
Giulia Marvaso*, Barbara Alicja Jereczek-Fossa*, Mattia Zaffaroni, Maria Giulia Vincini, Giulia Corrao, Nicolaus Andratschke, Ehsan H Balagamwala, Jens Bedke, Oliver Blanck, Umberto Capitanio, Rohann J M Correa, Gert De Meerleer, Ciro Franzese, Aurora Gaeta, Sara Gandini, Cristina Garibaldi, Peter C Gerszten, Silke Gillessen, William R Grubb, Matthias Guckenberger, Raquibul Hannan, Pavan M Jhaveri, Mirjana Josipovic, Linda G W Kerkmeijer, Eric J Lehrer, Magnus Lindskog, Alexander V Louie, Quynh-Nhu Nguyen, Piet Ost, David A Palma, Giuseppe Procopio, Maddalena Rossi, Michael Staehler, Alison C Tree, Yat Man Tsang, Nicholas Van As, Nicholas G Zaorsky, Thomas Zilli, David Pasquier†, Shankar Sivaâ€
doi : 10.1016/S1470-2045(24)00023-8
Volume 25, Issue 5, May 2024, Pages e193-e204
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Paula Rodriguez-Otero, Saad Usmani, Adam D Cohen, Niels W C J van de Donk, Xavier Leleu, Jaime Gállego Pérez-Larraya, Salomon Manier, Ajay K Nooka, Maria Victoria Mateos, Hermann Einsele, Monique Minnema, Michele Cavo, Benjamin A Derman, Noemi Puig, Francesca Gay, P Joy Ho, Wee-Joo Chng, Efstathios Kastritis, Gösta Gahrton, Katja Weisel, Chandramouli Nagarajan, Fredik Schjesvold, Joseph Mikhael, Luciano Costa, Noopur S Raje, Elena Zamagni, Roman Hájek, Niels Weinhold, Kwee Yong, Jing Christine Ye, Surbhi Sidhana, Giampaolo Merlini, Tom Martin, Yi Lin, Ajai Chari, Rakesh Popat, Jonathan L Kaufman, on behalf of the International Myeloma Working Group*
doi : 10.1016/S1470-2045(24)00043-3
Volume 25, Issue 5, May 2024, Pages e205-e216
Protecting Caribbean patients diagnosed with cancer from compounding disasters
Ana Patricia Ortiz*, C James Hospedales*, Pablo A Méndez-Lázaro, William M Hamilton, LaShae D Rolle, J Marshall Shepherd, Zelde Espinel, Hiram A Gay, Leticia M Nogueira†, James M Shultzâ€
doi : 10.1016/S1470-2045(24)00071-8
Volume 25, Issue 5, May 2024, Pages e217-e224
When leukaemia masquerades: the hidden syphilis diagnosis
Meryl Musicante, Julianna Martel Harrell, Shelby Kubicki, Jonathan L Curry, Anisha B Patel
doi : 10.1016/S1470-2045(24)00147-5
Volume 25, Issue 5, May 2024, Page e225
